Expanded Access Program (EAP)
Clinical trials and the subsequent approval of a therapy provide the best way to make therapies accessible to as many patients as possible. X4 Pharmaceuticals’ sole registered medicine is currently approved only in the United States.
Patients interested in any investigational product that has not yet been approved are encouraged to speak with their doctor and potentially participate in one of our current or future clinical trials. Please find information on our clinical trials by searching for X4 Pharmaceuticals at www.clinicaltrials.gov (in the United States) and https://euclinicaltrials.eu/search-clinical-trials-reports (in the European Union).
Currently, access to our unlicensed medicinal products may be provided only to patients outside of the United States who were enrolled in an X4-sponsored long-term extension of a trial at the time that trial was completed. A request for such access must be initiated by the treating physician through a written application and will be subject to the applicable national laws, regulations, and requirements.
We encourage you to stay informed regarding our development programs and we will continue to review our expanded access policy as needed.
For additional information, physicians with eligible patients can contact our Medical Information team at medicalinfo@x4pharma.com.